ERBB2 and breast carcinoma: The combination of ribociclib and endocrine therapy as a first-line treatment resulted in significantly improved overall survival (OS) compared to endocrine therapy alone, both in postmenopausal and premenopausal women with HR-positive/HER2-negative advanced breast cancer [4,5].